)
Edge26 Jun 2026
The Universal Language: Inventing the Barcode
How lines in the sand on a Miami beach became the most scanned symbol in human history, and why it took decades for anyone to care.
Nasus Pharma
Nasus Pharma (NSRX) investor relations material
Nasus Pharma Life Sciences Virtual Investor Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Life Sciences Virtual Investor Forum summary24 Jun, 2026
Technology overview
Nasax technology enables precise control of particle size and shape for optimal nasal absorption.
Powder formulation allows deep penetration into the nasal cavity, enhancing drug uptake.
Needle-free, dry powder design improves convenience, shelf life, and patient compliance.
Lead product and clinical progress
Lead product is an intranasal powder epinephrine (NS002) for anaphylaxis, entering phase III in Q4 2024.
Phase II studies showed faster and higher absorption than EpiPen, with superior onset of action.
Product maintains efficacy even under severe nasal congestion.
Market landscape and differentiation
Anaphylaxis market is large and growing due to rising allergy incidence, with a shift toward needle-free products.
Powder formulation offers faster absorption and higher efficacy compared to liquid and sublingual competitors.
Superior onset of action positions the product as a potential first-line therapy.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nasus Pharma
- Intranasal epinephrine shows rapid action, high patient preference, and strong market potential.NSRX
KOL event10 Jun 2026 - NS002 delivers epinephrine faster than EpiPen®, addressing a major unmet need in anaphylaxis care.NSRXCompany presentation10 Jun 2026
- Needle-free powder epinephrine achieves faster, superior absorption than EpiPen, with phase III starting Q4.NSRXBiotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026
- NS002 advances to pivotal study after strong Phase 2 data; cash runway secured through Q2 2027.NSRXQ4 202525 Mar 2026
- NS002 delivers epinephrine faster than EpiPen®, targeting unmet needs in a large anaphylaxis market.NSRXCompany presentation23 Mar 2026
- NS002 delivers epinephrine twice as fast as EpiPen, with strong safety and convenience benefits.NSRXStudy result16 Mar 2026
- Needle-free epinephrine powder shows faster absorption and strong market potential.NSRXLife Sciences Virtual Investor Forum11 Mar 2026
- Clinical-stage firm advancing intranasal powder drugs for emergencies, but faces ongoing losses and high risk.NSRXRegistration Filing2 Mar 2026
- NS002 delivers epinephrine faster and at higher levels than EpiPen, with strong safety and IP.NSRXCompany presentation25 Feb 2026
Next Nasus Pharma earnings date
Q1 20268 Jul, 2026
Nasus Pharma
Next Nasus Pharma earnings date
Q1 20268 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage